Lupin rolls out generic Doxil
Lupin is launching doxorubicin hydrochloride liposome injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, following Lupin’s alliance partner, ForDoz Pharma having received an approval from the Food and Drug Administration.
Doxorubicin hydrochloride liposome injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/ml) single-dose vials is a generic of Baxter Healthcare’s Doxil (liposomal).
[Read more: Lupin receives FDA OK for generic Banzel]
It is indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome-related Kaposi’s Sarcoma and multiple myeloma.
Doxorubicin hydrochloride liposome injection had a market value of roughly $40.9 million, per IQVIA June 2024 data.
[Read more: Lupin receives FDA OK for generic Banzel]